MX2023011664A - Forma cristalina de un inhibidor de shp2. - Google Patents

Forma cristalina de un inhibidor de shp2.

Info

Publication number
MX2023011664A
MX2023011664A MX2023011664A MX2023011664A MX2023011664A MX 2023011664 A MX2023011664 A MX 2023011664A MX 2023011664 A MX2023011664 A MX 2023011664A MX 2023011664 A MX2023011664 A MX 2023011664A MX 2023011664 A MX2023011664 A MX 2023011664A
Authority
MX
Mexico
Prior art keywords
crystalline form
shp2 inhibitor
relates
compositions
dihydrospiro
Prior art date
Application number
MX2023011664A
Other languages
English (en)
Inventor
Katie Keaton Brown
Aaron Keith Goodwin
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2023011664A publication Critical patent/MX2023011664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención se refiere a una forma cristalina del hemihidrato de base libre de (S)-1'-(6-((2-amino-3-cloropiridin-4-il)tio)-1,2, 4-triazin-3-il)-1,3-dihidroespiro[indeno-2,4'-piperidin]-1-amina (Forma 1). La invención también se refiere a composiciones farmacéuticas que comprenden esta forma cristalina, y a métodos para usar la forma cristalina y tales composiciones para el tratamiento de crecimiento celular anormal, tal como cáncer, en un mamífero.
MX2023011664A 2021-04-01 2022-03-30 Forma cristalina de un inhibidor de shp2. MX2023011664A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169340P 2021-04-01 2021-04-01
US202263321902P 2022-03-21 2022-03-21
PCT/IB2022/052982 WO2022208408A1 (en) 2021-04-01 2022-03-30 Crystalline form of a shp2 inhibitor

Publications (1)

Publication Number Publication Date
MX2023011664A true MX2023011664A (es) 2023-10-11

Family

ID=81327112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011664A MX2023011664A (es) 2021-04-01 2022-03-30 Forma cristalina de un inhibidor de shp2.

Country Status (9)

Country Link
US (1) US20240190843A1 (es)
EP (1) EP4313307A1 (es)
JP (1) JP2024513798A (es)
KR (1) KR20230165309A (es)
AU (1) AU2022252094B2 (es)
BR (1) BR112023019479A2 (es)
CA (1) CA3215295A1 (es)
MX (1) MX2023011664A (es)
WO (1) WO2022208408A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3678703A1 (en) 2017-09-07 2020-07-15 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
EP3973271A1 (en) 2018-09-14 2022-03-30 Unilever IP Holdings B.V. Evaluating the efficacy of leave-on cosmetic compositions to protect skin from pollutants
MA55511A (fr) 2019-04-02 2022-02-09 Array Biopharma Inc Inhibiteurs de protéine tyrosine phosphatase

Also Published As

Publication number Publication date
BR112023019479A2 (pt) 2023-12-05
KR20230165309A (ko) 2023-12-05
US20240190843A1 (en) 2024-06-13
CA3215295A1 (en) 2022-10-06
JP2024513798A (ja) 2024-03-27
EP4313307A1 (en) 2024-02-07
AU2022252094A1 (en) 2023-10-12
WO2022208408A1 (en) 2022-10-06
AU2022252094B2 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
MX2023011664A (es) Forma cristalina de un inhibidor de shp2.
EP3463343B1 (en) Heterocyclic inhibitors of ptpn11
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20125589B (en) TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
RS20050180A (en) Novel benzoimidazole derivatives useful as antiproliferative agensts
RS20080272A (en) Pyramidine derivatives for the treatment of abnormal cell growth
RS20060097A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200510380A (en) Mitotic kinesin inhibitors
GEP20074213B (en) Novel inhibitors of kinases
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2007003319A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2009012847A (es) Analogos dipeptidicos como inhibidores de factores de coagulacion.
MX2007007032A (es) Compuestos de aminopirimidina y metodos de uso.
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2004004632A3 (en) Flavone derivatives as inhibitors of cyclin-dependent kinases
RU2006128788A (ru) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
RU2008104510A (ru) Производные индолилмалеинимида
MXPA06000300A (es) Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina.
MXPA05009303A (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.